KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer.

Rushabh Kothari, Maulik Doshi, P K Chaithanya, Satheesh Ct, Anil Kumar, Krishna Mohan Mallavarapu, Rajnish Nagarkar, Vijay Mahobia, Niraj Bhatt, K L Priyadarshini, Ajay Gogia, Tanveer Maksud, Saurabh Prasad, K Velavan, Rajeev L K, Prakash Ss, Vikas Talreja, Kaushal Kalra, Bhushan Nemade, Aloke Ghosh Dastidar, Tarachand Gupta, Tushar Patil, Shailesh Bondarde, Pinakin Patel, Sudeep Gupta, Ghanashyam Biswas, Manan Vaghela, Pinaki Mahato, Honey Parekh, Mahesh Kalloli, Rachan Shetty, Gaurav Prakash, Anil Goel, Srikrishna Mandal, Tamohan Choudhury, Minish Jain, Chanchal Goswami, Yathish Kumar H M, K K Mukherjee, Rahul Shrivastava, Deven Parmar

Clin Breast Cancer 24(7) 639-646.e2

PMID39069436
PMCID-
DOI10.1016/j.clbc.2024.07.001
发表日期2024-07-28
入排依据:The record describes a Phase III, randomized, double-blind clinical trial in human oncology (HER2-positive metastatic breast cancer) with a drug intervention (ZRC-3277, a pertuzumab biosimilar). It is an original result report. However, the primary efficacy endpoint is objective response rate (ORR), and no time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) is reported or designated as a primary or key secondary objective. Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint.
摘要

摘要

INTRODUCTION: To evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) with Perjeta® (pertuzumab) in previously untreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). PATIENTS AND METHODS: This phase III, multicenter, double-blind study across 38 sites in India randomized (1:1) patients with HER2-positive MBC in either the ZRC-3277 or Perjeta® group. Both groups also received trastuzumab and docetaxel. Of 268 enrolled patients, mITT population had 243 patients (119 and 124 in the ZRC-3277 and Perjeta® groups, respectively). The primary objective was to compare the between-group objective response rate (ORR) after 6 cycles of treatment. ORR was determined by evaluating scans of computed tomography or magnetic resonance imaging following Response Evaluation Criteria in Solid Tumor (RECIST 1.1). Two-sided 95% confidence interval (95% CI) for the difference in ORR was determined to evaluate the noninferiority of ZRC-3277 to Perjeta®. The secondary outcomes included the assessment of PK, immunogenicity, and safety between the 2 groups. RESULTS: In the mITT population, 104 (87.39%) and 114 (91.94%) participants achieved the ORR in the ZRC-3277 and Perjeta® groups, respectively. For predefined -15% noninferiority margin, obtained 2-sided 95% CIs (-12.19%, 3.11%) for the difference in ORR (-4.55%) between the 2 groups demonstrated the noninferiority of ZRC-3277 to Perjeta®. PK, immunogenicity, and safety were not significantly different between the 2 groups. CONCLUSION: Efficacy, PK, immunogenicity, and safety profiles of ZRC-3277 was found to be similar to those of Perjeta®.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。